392.1002



Re: Application of:

Hiroyuki ABURATANI et al.

Serial No.:

10/526,741

Filed:

March 4, 2005

For:

ANTIBODY AGAINST SECRETED N-

TERMINAL PEPTIDE OF GPC3 PRESENT IN **BLOOD OR C-TERMINAL PEPTIDE OF GPC3**

MAIL STOP: PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

November 10, 2005

INFORMATION DISCLOSURE STATEMENT

SIR:

In accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicant hereby makes of record the documents listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the references which were cited in the International Search Report, in the above-identified international application, a copy of which International Search Report is enclosed along with a translation of the International Preliminary Examination Report, are enclosed herewith.

This information disclosure statement is being submitted before a first Office Action on the merits, and, therefore, under 37 C.F.R. § 1.97(b), no fee is due. If any fees are due at this time, the Assistant Commissioner is authorization to charge such fees to Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

DAVIDSON, DAVIDSON & KAPPEL, LLC 485 Seventh Avenue, 14th Floor New York, NY 10018 (212) 736-1940

of 1995, no persons are required to respond to a collection of information

ough 07/31/2006. OMB 0651-0031 DEPARTMENT OF COMMERCE t contains a valid OMB control number.

Under the Paperwork Redu

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2

Complete if Known				
Application Number	10/526,741			
Filing Date	March 4, 2005			
First Named Inventor	Hiroyuki ABURATANI, et al.			
Art Unit	Not Yet Known			
Examiner Name	Not Yet Known			
Attorney Docket Number	392.1002			

	U.S. PATENT DOCUMENTS					
Examiner Cite		Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant	
Initials * No	No.1	No. 1 Number - Kind Code² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
		US-				
		US-				
		US-	•			
		US-				
		US-				
,		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY			T [®]
		WO 03/000883 A1	01-03-2003	Chugai Pharmaceutical		
		WO 03/010336 A2	02-06-2003	DEBUSCHEWITZ, et al.		
						-
					-	
		l		ł		

Examiner Signature		Date Considered		
-----------------------	--	--------------------	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \(^6\) Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection or information is required by 37 CFR 1.97 and 1.96. The miorination is required to obtain or terain a benefit by the public which is one can be used to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03) rough 07/31/2006. OMB 0651-0031 Approved for u

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/526,741 INFORMATION DISCLOSURE Filing Date March 4, 2005 STATEMENT BY APPLICANT First Named Inventor Hiroyuki ABURATANI, et al. Art Unit Not Yet Known (Use as many sheets as necessary) Examiner Name Not Yet Known Sheet 2 of Attorney Docket Number 392.1002

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		M.I. CAPPURO, et al, Overexpression of Glypican-3 in Human Hepatocellular Carcinomas Determined by Immunohitochemistry Using a Monoclonal Antibody, Proceedings of the American Association for Cancer Research Annual Meeting, March 2002, Vol. 43, pg. 219	
		Y. MIDORIKAWA, et al., Glypican-3, Overexpressed in Hepato-Cellular Carcinoma, Modulates FGF2 and BMP-& Signaling, International Journal of Cancer, February 10, 2003, Vol. 103, No. 4, pp. 455-465	
		Y.K. SUNG, et al., Glypican-3 is Overexpressed in Human Hepatocellular Carcinoma, Cancer Science, March 2003, Vol. 94, No. 3, pp. 259-262	
		M. CAPURRO, et al., Glypican-3: A Novel Serum and Histochemical Marker for Hepatocellular Carcinoma, Gastroenterology, July 2003, Vol. 125(1), pp. 89-97	
		H. LAGE, et al., Cloning and Characterization of Human cDNAs Encoding a Protein with High Homology to rat intestical development protein OCI-5', Gene, 1997, Vol. 188, pp. 151-156	
	-		

Examiner	Date	
Signature	Considered	
0.3.12.12.0	 00110100100	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.